1. Home
  2. LFMD vs CGEN Comparison

LFMD vs CGEN Comparison

Compare LFMD & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LifeMD Inc.

LFMD

LifeMD Inc.

HOLD

Current Price

$3.14

Market Cap

218.1M

Sector

Health Care

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$2.58

Market Cap

191.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LFMD
CGEN
Founded
1994
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
218.1M
191.1M
IPO Year
2012
2001

Fundamental Metrics

Financial Performance
Metric
LFMD
CGEN
Price
$3.14
$2.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
2
Target Price
$9.14
$5.00
AVG Volume (30 Days)
1.0M
284.0K
Earning Date
05-06-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
141.67
N/A
EPS
N/A
N/A
Revenue
$12,468,578.00
N/A
Revenue This Year
$17.52
N/A
Revenue Next Year
$18.73
$75.09
P/E Ratio
N/A
N/A
Revenue Growth
49.79
N/A
52 Week Low
$2.60
$1.30
52 Week High
$7.32
$3.24

Technical Indicators

Market Signals
Indicator
LFMD
CGEN
Relative Strength Index (RSI) 35.75 60.66
Support Level $3.00 $2.54
Resistance Level $3.41 $3.05
Average True Range (ATR) 0.25 0.11
MACD 0.00 0.02
Stochastic Oscillator 14.20 64.39

Price Performance

Historical Comparison
LFMD
CGEN

About LFMD LifeMD Inc.

LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Share on Social Networks: